Press Releases April 23, 2026 04:30 PM

Eos Energy Enterprises Announces Date for First Quarter 2026 Financial Results and Conference Call; Announces Participation at Upcoming Investor Conferences

Eos Energy Enterprises announces Q1 2026 earnings release date and upcoming investor conference participation.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
EOSE

Eos Energy Enterprises, a US-based innovator in zinc-based battery energy storage systems, will release its Q1 2026 financial results on May 13, 2026, followed by a conference call with shareholder engagement. The company also announced its participation in the Stifel 2026 Boston Cross Sector Conference and the J.P. Morgan Natural Resources Conference to discuss its business and industry outlook.

Eos Energy Enterprises Announces Date for First Quarter 2026 Financial Results and Conference Call; Announces Participation at Upcoming Investor Conferences
EOSE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Eos will release Q1 2026 financial results before market open on May 13, 2026, with a live conference call that includes shareholder Q&A via Say Technologies platform.
  • The company will participate in two major investor conferences in June 2026, providing opportunities for direct investor engagement and exposure.
  • Eos focuses on zinc-based battery energy storage systems with its patented Znyth™ technology, supporting utility-scale, microgrid, commercial, and industrial energy storage applications, contributing to the energy storage and renewable energy sectors.

EDISON, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced it will release its first quarter 2026 financial results before the U.S. market opens on May 13, 2026. A conference call to discuss its results will take place the same morning at 8:30 a.m. Eastern Time.

Eos partners with Say Technologies to allow retail and institutional shareholders to submit and vote on questions ahead of the earnings call. A selection of key questions applicable to the broad investor base will be addressed live during the call, offering shareholders an opportunity to engage with Eos management.

Beginning on April 27, 2026, at 9:00 a.m. Eastern Time, registered shareholders will be able to submit questions via the Say Technologies Q&A Platform which will remain open until 5:00 p.m. Eastern Time on May 10, 2026. For any support inquires shareholders may email support@saytechnologies.com.

Concurrently, the Company also announced its participation at two upcoming investor conferences.

Stifel 2026 Boston Cross Sector 1x1 Conference
Chief Executive Officer Joe Mastrangelo will participate in a panel discussion at the Stifel 2026 Boston Cross Sector 1x1 Conference Tuesday, June 2, 2026. The event will also include 1x1 investor meetings.

J.P. Morgan Natural Resources Conference: An Energy, Power, Renewables & Mining Event
Chief Executive Officer Joe Mastrangelo will participate in a fireside chat hosted by Mark Strouse on Tuesday, June 23, 2026. The event will also include 1x1 investor meetings.

Investors seeking to engage in these industry events should reach out directly to their representatives at Stifel and J.P. Morgan.

Registration Information

The live webcast of the earnings call will be available on the “Investor Relations” page of the Company’s website at Eos Investors or may be accessed using this link (Registration Link). To avoid delays, we encourage participants to join the conference call fifteen minutes ahead of the scheduled start time.

The conference call replay will be available via webcast through Eos’ investor relations website for twelve months following the live presentation. The webcast replay will be available from approximately 11:30 a.m. Eastern Time on May 13, 2026, and can be accessed by visiting Eos Investors.

About Eos Energy Enterprises
Eos is accelerating the shift to American energy independence with positively ingenious solutions that transform how the world stores power. The Company’s BESS features the innovative Znyth™ technology, a proven chemistry with readily available non-precious earth components, that is the pre-eminent safe, non-flammable, secure, stable, and scalable alternative to conventional technology. The Company’s BESS is ideal for utility-scale, microgrid, commercial, and industrial long-duration energy storage applications (i.e., 4 to 16+ hours) and provides customers with significant operational flexibility to cost effectively address current and future increased grid demand and complexity. For more information about Eos (NASDAQ: EOSE), visit eose.com.

Contacts        

Investors:ir@eose.comMedia:media@eose.com



Risks

  • Financial performance may not meet market expectations in Q1 2026, potentially impacting stock valuation in the energy storage and clean energy sectors.
  • Dependence on technology adoption and scaling of zinc-based battery systems, which may face competition from alternative energy storage technologies.
  • Market conditions and regulatory policies affecting the energy storage and renewables sectors may pose uncertainty for Eos's growth and operational flexibility.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026